- Home
- TPIC vs ASRT Comparison
TPIC vs ASRT Comparison
Compare TPIC & ASRT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TPIC
- ASRT
- Stock Information
- Founded
- TPIC 1968
- ASRT 1995
- Country
- TPIC United States
- ASRT United States
- Employees
- TPIC N/A
- ASRT N/A
- Industry
- TPIC Industrial Machinery/Components
- ASRT Biotechnology: Pharmaceutical Preparations
- Sector
- TPIC Industrials
- ASRT Health Care
- Exchange
- TPIC Nasdaq
- ASRT Nasdaq
- Market Cap
- TPIC 65.6M
- ASRT 65.7M
- IPO Year
- TPIC 2016
- ASRT 1997
- Fundamental
- Price
- TPIC $0.73
- ASRT $0.61
- Analyst Decision
- TPIC Hold
- ASRT Strong Buy
- Analyst Count
- TPIC 6
- ASRT 3
- Target Price
- TPIC $1.86
- ASRT $3.08
- AVG Volume (30 Days)
- TPIC 684.9K
- ASRT 480.8K
- Earning Date
- TPIC 05-08-2025
- ASRT 05-05-2025
- Dividend Yield
- TPIC N/A
- ASRT N/A
- EPS Growth
- TPIC N/A
- ASRT N/A
- EPS
- TPIC N/A
- ASRT N/A
- Revenue
- TPIC $1,331,131,000.00
- ASRT $124,961,000.00
- Revenue This Year
- TPIC $8.93
- ASRT N/A
- Revenue Next Year
- TPIC $9.59
- ASRT $11.20
- P/E Ratio
- TPIC N/A
- ASRT N/A
- Revenue Growth
- TPIC N/A
- ASRT N/A
- 52 Week Low
- TPIC $0.64
- ASRT $0.51
- 52 Week High
- TPIC $5.75
- ASRT $1.80
- Technical
- Relative Strength Index (RSI)
- TPIC 40.56
- ASRT 39.17
- Support Level
- TPIC $0.73
- ASRT $0.58
- Resistance Level
- TPIC $0.92
- ASRT $0.80
- Average True Range (ATR)
- TPIC 0.09
- ASRT 0.05
- MACD
- TPIC 0.01
- ASRT 0.00
- Stochastic Oscillator
- TPIC 31.10
- ASRT 34.48
About TPIC TPI Composites Inc.
TPI Composites Inc is engaged in manufacturing composite wind blades. The company operates in wind energy and transportation industries where it manufactures structures for a bus, rail, theme parks, and trucks. Geographically the segments are divided into the U.S, Asia, Mexico, EMEA and India where the Mexico segment derives a majority of revenue.
About ASRT Assertio Holdings Inc.
Assertio Holdings Inc is a pharmaceutical company. It is engaged in providing solutions to advance patient care in the areas of neurology, orphan and specialty medicines. The company markets three FDA-approved products for various neurological conditions including Gralise, tablets for the management of postherpetic neuralgia; CAMBIA, for acute treatment of migraine attacks with or without aura in adults of age or older and Zipsor, liquid-filled capsules for relief of mild to moderate pain.